Other Early Stage Assets
Bi-specific antibodies generated from Evive’s ITabTM platform simultaneously bind to CD3 molecules on human T cells and to specific tumor antigens, forming a synapsis between a tumor cell and T cells linked by the ITabTM antibodies. The formation of a synapsis leads to activation of T cells, and the release of mediators lysing the tumor cells. The ITabTM antibody can drive the expansion of T cells rendering T cells as serial killers of tumor cells.
A-319 is a bi-specific antibody (BsAb) designed to target CD19 and CD3 (anti-CD19, anti-CD3) and is under development for the treatment of patients with B cell malignancies including ALL, CLL, Lymphoma. A-319 activates the immune system, specifically T cells in a patient, to kill B cells. The China Phase I IND application has been filed with CFDA.